AU2022272316A1 - Adenoviral helper plasmid - Google Patents

Adenoviral helper plasmid Download PDF

Info

Publication number
AU2022272316A1
AU2022272316A1 AU2022272316A AU2022272316A AU2022272316A1 AU 2022272316 A1 AU2022272316 A1 AU 2022272316A1 AU 2022272316 A AU2022272316 A AU 2022272316A AU 2022272316 A AU2022272316 A AU 2022272316A AU 2022272316 A1 AU2022272316 A1 AU 2022272316A1
Authority
AU
Australia
Prior art keywords
seq
helper plasmid
adenoviral helper
nucleotide sequence
adenoviral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022272316A
Other languages
English (en)
Inventor
David DISMUKE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forge Biologics Inc
Original Assignee
Forge Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forge Biologics Inc filed Critical Forge Biologics Inc
Publication of AU2022272316A1 publication Critical patent/AU2022272316A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AU2022272316A 2021-05-13 2022-05-13 Adenoviral helper plasmid Pending AU2022272316A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163188294P 2021-05-13 2021-05-13
US63/188,294 2021-05-13
PCT/US2022/029193 WO2022241215A2 (en) 2021-05-13 2022-05-13 Adenoviral helper plasmid

Publications (1)

Publication Number Publication Date
AU2022272316A1 true AU2022272316A1 (en) 2023-11-30

Family

ID=84029842

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022272316A Pending AU2022272316A1 (en) 2021-05-13 2022-05-13 Adenoviral helper plasmid

Country Status (9)

Country Link
US (1) US20250019667A1 (https=)
EP (1) EP4337236A4 (https=)
JP (1) JP2024518553A (https=)
KR (1) KR20240036508A (https=)
CN (1) CN117897167A (https=)
AU (1) AU2022272316A1 (https=)
CA (1) CA3218342A1 (https=)
IL (1) IL308472A (https=)
WO (1) WO2022241215A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4619018A2 (en) * 2022-11-16 2025-09-24 Forge Biologics, Inc. Adenoviral helper plasmid
CN119842820A (zh) * 2023-10-16 2025-04-18 深圳市深研生物科技有限公司 用于生产重组腺相关病毒载体的方法及包装/生产细胞

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223391A (en) * 1990-02-21 1993-06-29 President And Fellows Of Harvard College Inhibitors of herpes simplex virus replication
US5543264A (en) * 1990-06-29 1996-08-06 Associated Universities, Inc. Co-factor activated recombinant adenovirus proteinases
US6670188B1 (en) * 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
AU2001257611A1 (en) * 2000-04-28 2001-11-12 Avigen, Inc. Polynucleotides for use in recombinant adeno-associated virus virion production
US7754201B2 (en) * 2000-06-02 2010-07-13 GenPhar, Inc Method of vaccination through serotype rotation
EP2336339A3 (en) * 2000-09-25 2011-09-14 The Regents of the University of Michigan Production of viral vectors
US20040197347A1 (en) * 2002-09-23 2004-10-07 Board Of Regents, The University Of Texas System Methods for vaccine identification and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of the herpesvirus family
WO2004083418A1 (en) * 2003-03-17 2004-09-30 Merck & Co., Inc. Adenovirus serotype 24 vectors, nucleic acids and virus produced thereby
US20050118683A1 (en) * 2003-06-11 2005-06-02 Wood Clive R. Method for producing a polypeptide
US20080063656A1 (en) * 2004-08-09 2008-03-13 Emini Emilio A Adenoviral Vector Compositions
CN103436507B (zh) * 2006-05-05 2016-04-20 冈戈根股份有限公司 噬菌体衍生的抗微生物活性剂
EP2463362B1 (en) * 2007-11-28 2017-11-08 The Trustees Of The University Of Pennsylvania Simian subfamily c adenovirus SAdv-31 and uses thereof
WO2010115172A2 (en) * 2009-04-03 2010-10-07 University Of Washington Antigenic peptide of hsv-2 and methods for using same
US20120171191A1 (en) * 2009-05-26 2012-07-05 Cellectis Meganuclease variants cleaving the genome of a pathogenic non-integrating virus and uses thereof
US20110293511A1 (en) * 2009-09-29 2011-12-01 Terrance Grant Johns Specific binding proteins and uses thereof
WO2018017925A1 (en) * 2016-07-22 2018-01-25 President And Fellows Of Harvard College Targeting lytic and latent herpes simplex virus 1 infection with crispr/cas9
KR102652494B1 (ko) * 2017-07-18 2024-03-28 제노비에 에이비 전장 t-세포 수용체 오픈 리딩 프레임의 신속한 조립 및 다양화를 위한 2-성분 벡터 라이브러리 시스템
US12370269B2 (en) * 2018-03-02 2025-07-29 University Of Florida Research Foundation, Incorporated Retinal protective factor 2 (RPF2) protein delivered by adeno-associated virus expression
EP3784785A4 (en) * 2018-04-23 2022-02-16 Duke University DOWNREGULATION OF SNCA EXPRESSION BY TARGETED EDITING OF DNA METHYLATION
US20210324415A1 (en) * 2018-10-09 2021-10-21 Nikegen, Llc Compositions and methods for preparing viral vectors
GB201816919D0 (en) * 2018-10-17 2018-11-28 Glaxosmithkline Ip Dev Ltd Adeno-associated viral vector producer cell lines
SG10201906637UA (en) * 2019-07-17 2021-02-25 Agency Science Tech & Res Treatment/prevention of disease by linc complex inhibition
CN114761030A (zh) * 2019-11-01 2022-07-15 休斯敦系统大学 具有诱导的抗肿瘤免疫的溶瘤病毒疗法
US11130787B2 (en) * 2020-06-11 2021-09-28 MBF Therapeutics, Inc. Alphaherpesvirus glycoprotein d-encoding nucleic acid constructs and methods

Also Published As

Publication number Publication date
EP4337236A2 (en) 2024-03-20
KR20240036508A (ko) 2024-03-20
CA3218342A1 (en) 2022-11-17
IL308472A (en) 2024-01-01
JP2024518553A (ja) 2024-05-01
EP4337236A4 (en) 2025-04-16
CN117897167A (zh) 2024-04-16
WO2022241215A3 (en) 2023-02-02
US20250019667A1 (en) 2025-01-16
WO2022241215A2 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
US20220127621A1 (en) Fusion proteins and fusion ribonucleic acids for tracking and manipulating cellular rna
AU2023379677A1 (en) Adenoviral helper plasmid
CN110997912A (zh) 用于改进的细胞转染和/或rAAV载体生产的增强剂
EP3294891B1 (en) Polynucleotides, vectors and methods for insertion and expression of transgenes
US11814642B2 (en) Manufacturing and use of recombinant AAV vectors
US20250019667A1 (en) Adenoviral helper plasmid
CN113302291A (zh) 使用逆转录病毒整合酶-Cas9融合蛋白通过定向非同源DNA插入进行的基因组编辑
WO2020142714A1 (en) Aav expression cassette and aav vectors comprising the same
EP3943512A1 (en) Fusion protein for enhancing gene editing and use thereof
TW202116794A (zh) 用於生物製造之合成遺傳因子
US20250295814A1 (en) Compositions and methods for modifying dux4
WO2021189110A1 (en) Dna altering proteins and uses therefor
WO2021230385A1 (en) Method for treating muscular dystrophy by targeting utrophin gene
WO2024103118A1 (en) Gene editing systems and uses therefor
WO2023147558A2 (en) Crispr methods for correcting bag3 gene mutations in vivo
WO2022170146A1 (en) Vectors comprising stuffer polynucleotide sequences
WO2026010927A2 (en) Producer cells for safer aav production
WO2026072721A1 (en) Parvovirus compositions and methods for gene therapy
WO2024192274A2 (en) On cas template synthesis (ocats) systems and uses thereof
TW202408593A (zh) 用於在肝臟中去靶向基因表現之元件
WO2026085335A2 (en) Bidirectional rep-cap plasmid for production of aav
KR20250007592A (ko) 아데노-관련 바이러스 패키징 벡터 및 이의 사용 방법
WO2024091907A1 (en) Compositions and methods for modifying the hpv16 genome
WO2026064428A2 (en) Capsid polypeptides and methods of use thereof
CN120936723A (zh) 改进的重组多腺苷酸化信号序列及其用途